0

Explore original, structured summaries for research and education.

Research profile

Dihexa(N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide)

(N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide)

Dihexa(N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is indexed as a Modified oligopeptide research entry. Its current evidence category is (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide), and published discussion commonly places it within Cognitive, Longevity. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.

CognitiveLongevity

Identity

Molecular Data

Molecular weight
504.7 Da
Chain length
—
Type
Modified oligopeptide
Reported half-life
8-12 days
Amino-acid sequenceHexanoyl-Tyr-Ile-Ahx-NH2

Literature map

Research indications

Cognitive

  • Memory Enhancementmost effective
  • Learning Accelerationmost effective
  • Cognitive Recoveryeffective

Neuroprotection

  • Amyloid Reductioneffective
  • Neuroinflammation Reductioneffective
  • Synaptic Preservationeffective

Neuroplasticity

  • Dendritic Spine Formationmoderate
  • BDNF Upregulationmoderate
  • Angiogenesis Promotionmoderate

Evidence-gated guidance

Dosing Protocols

No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.

Dose
Not established on this profile
Frequency
Not established on this profile
Cycle
Not established on this profile
Storage
Follow the exact supplier or authorized product documentation; requirements vary by formulation
Open peptide calculator →

Combination risks

Interactions

Evidence status

No independently verified interaction table is available here for Dihexa(N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.

Do not infer compatibility

Being listed beside another compound does not mean that combining them is safe or effective.

Evidence-informed overview

What to Expect

Evidence boundary

Research indications describe topics studied in the literature; they do not predict an individual outcome.

Clinical monitoring

Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.

Risk overview

Side Effects & Safety

The safety profile of Dihexa(N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.

Verification

Quality Checklist

  1. Confirm exact chemical identity, sequence, salt form, and concentration.
  2. Require a batch-specific certificate of analysis with named test methods and results.
  3. Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
  4. For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.

Clear answers

Frequently Asked Questions

Is Dihexa(N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) approved for personal use?

This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.

Why is no dose listed?

A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.

Do research indications prove effectiveness?

No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.

Source trail

References

  1. Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia AgentsMcCoy AT, Benoist CC, Wright JW, Harding JW · Journal of Pharmacology and Experimental Therapeutics · 2013
  2. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling PathwayGao Y, Zhang Y, Wang Z, et al. · Brain Research Bulletin · 2021
  3. The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met SystemBenoist CC, Kawas LH, Zhu M, Bhatt D, Wright JW, Harding JW · Journal of Pharmacology and Experimental Therapeutics · 2014
  4. The Development of Small Molecule Angiotensin IV Analogs to Treat Alzheimer's and Parkinson's DiseasesWright JW, Harding JW · Progress in Neurobiology · 2015

View the structural source profile ↗